2 weeks Ago By ABMN Staff
Long Focus Capital Management LLC lifted its holdings in shares of Aura Biosciences, Inc. ( NASDAQ:AURA – Free Report ) by 113.4% during the second quarter, according to the company in its most recent Form 13F filing with the SEC.
The firm owned 1,057,188 shares of the company’s stock after purchasing an additional 561,766 shares during the period. Long Focus Capital Management LLC owned 2.13% of Aura Biosciences worth $7,992,000 as of its most recent filing with the SEC.
Other institutional investors also recently modified their holdings of the company. American Century Companies Inc. bought a new stake in Aura Biosciences in the second quarter valued at approximately $119,000.
American International Group Inc. increased its position in shares of Aura Biosciences by 27.4% during the first quarter.
American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after buying an additional 3,782 shares during the period. Virtu Financial LLC bought a new position in Aura Biosciences during the first quarter worth $144,000.
Trexquant Investment LP lifted its holdings in Aura Biosciences by 64.5% in the fourth quarter. Trexquant Investment LP now owns 17,362 shares of the company’s stock valued at $154,000 after buying an additional 6,809 shares during the period.
Finally, Rhumbline Advisers boosted its position in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after acquiring an additional 18,011 shares during the last quarter.
Institutional investors own 96.75% of the company’s stock. Aura Biosciences Price Performance Shares of NASDAQ AURA opened at $9.
01 on Friday. Aura Biosciences, Inc. has a 1 year low of $5.
99 and a 1 year high of $12.35. The stock has a market capitalization of $446.
38 million, a P/E ratio of -4.84 and a beta of 0.35.
The company has a 50-day moving average price of $8.70 and a 200-day moving average price of $7.91.
Wall Street Analysts Forecast Growth A number of brokerages have recently issued reports on AURA. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 9th. Evercore ISI upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th.
JMP Securities lifted their price objective on shares of Aura Biosciences from $19.00 to $23.00 and gave the company a “market outperform” rating in a research note on Friday, September 13th.
Finally, HC Wainwright restated a “buy” rating and issued a $21.00 price target on shares of Aura Biosciences in a report on Friday, September 13th. Three equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company.
According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $21.67.
Get Our Latest Stock Analysis on AURA Aura Biosciences Company Profile ( Free Report ) Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Featured Articles Want to see what other hedge funds are holding AURA? Visit HoldingsChannel.
com to get the latest 13F filings and insider trades for Aura Biosciences, Inc. ( NASDAQ:AURA – Free Report ). Receive News & Ratings for Aura Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aura Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
